监事会决议公告 证券代码：300653 证券简称：正海生物 公告编号：2025-031 烟台正海生物科技股份有限公司 第四届监事会第七次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、监事会会议召开情况 烟台正海生物科技股份有限公司（以下简称"公司"）第四届监事会第七次 会议于 2025 年 8 月 4 日以通讯的方式召开，会议通知已于 2025 年 7 月 24 日以 电子邮件形式向全体监事发出。本次会议应到监事 3 人，实到 3 人，其中许月莉 女士、潘励山先生、宋广平先生以通讯方式出席会议，会议由许月莉女士主持。 会议的出席人数、召开和表决方式符合《中华人民共和国公司法》等法律法规及 《烟台正海生物科技股份有限公司章程》的相关规定，合法有效。 二、监事会会议审议情况 经与会监事研究，会议审议通过了如下决议： 1、关于 2025 年半年度报告全文及其摘要的议案 经审核，监事会认为董事会编制和审核公司《2025 年半年度报告全文》及 其摘要的程序符合法律、行政法规和中国证监会的规定，报告内容真实、准确、 完整地反映了公司的实际情况，不存在任 ...

董事会决议公告 证券代码：300653 证券简称：正海生物 公告编号：2025-030 烟台正海生物科技股份有限公司 第四届董事会第八次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、董事会会议召开情况 烟台正海生物科技股份有限公司（以下简称"公司"）第四届董事会第八次 会议于 2025 年 8 月 4 日以通讯方式召开，会议通知已于 2025 年 7 月 24 日以电 子邮件形式向全体董事发出，本次会议应参会董事 8 人，实参会董事 8 人（其中 独立董事李江华先生因工作原因无法出席会议，委托独立董事宋希亮先生代为出 席会议并行使表决权，其中以通讯表决方式出席会议的人数为 7 人，分别为郭焕 祥、董群、宋侃、赵丽、张超、宋希亮、王辉）。会议由郭焕祥先生主持，监事 许月莉、潘励山、宋广平列席会议。会议出席人数、召开和表决方式符合《公司 法》等法律、法规及《公司章程》的相关规定，合法有效。 二、董事会会议审议情况 经与会董事研究，会议审议通过了如下决议： 1、关于 2025 年半年度报告全文及其摘要的议案 公司《2025 年半年度报告全文》及《 ...

智通财经APP讯，正海生物(300653.SZ)发布2025年半年度报告，该公司营业收入为1.88亿元，同比减少 5.14%。归属于上市公司股东的净利润为4648.57万元，同比减少45.97%。归属于上市公司股东的扣除非 经常性损益的净利润为4028.07万元，同比减少46.77%。基本每股收益为0.26元。 ...

正海生物公告，2025年上半年营业收入1.88亿元，同比下降5.14%。净利润4648.57万元，同比下降 45.97%。 ...

烟台正海生物科技股份有限公司 烟台正海生物科技股份有限公司 2025 年半年度报告全文 2025 年半年度报告 2025-029 【2025 年 8 月 5 日】 1 烟台正海生物科技股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人郭焕祥、主管会计工作负责人赵丽及会计机构负责人(会计主 管人员)赵丽声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 1、成长性风险 公司专注于再生医学相关产品的研发及产业化，以自主创新的核心技术 开发出的口腔修复膜和脑膜产品，是目前公司业务收入的主要来源，两款产 品的良好口碑和不断扩大的品牌影响力使其在临床应用上获得了越来越广泛 的赞誉，同时也逐步感受到市场环境变化、竞争加剧等因素带来的压力和挑 战。公司结合市场需求及自身技术积淀，相继启动了钙硅生物陶瓷骨修复材 料、宫腔修复膜、乳房补片、人脐带间充质干细胞等新产品的梯队研发，并 在基因工程、 ...

Core Viewpoint - Zhenghai Biological has experienced significant shareholder reductions despite its ongoing growth and strong financial performance, raising concerns about market confidence and future stability [1][4][8]. Shareholder Reduction - The controlling shareholder, Mi Bohai, has reduced his stake by 5% from August 5 to February 3, resulting in a decrease from 42.53% to 37.53% [7]. - Longwood, the second-largest shareholder, has also been reducing its holdings, with its stake dropping to 9.27% [7]. - Together, the two major shareholders have cashed out approximately 5.77 billion yuan, with Mi Bohai realizing about 3.70 billion yuan and Longwood about 2.07 billion yuan [7][8]. Financial Performance - Zhenghai Biological has shown consistent revenue and net profit growth since 2013, with a projected annual revenue of 3.38 billion yuan and a net profit of 1.31 billion yuan for 2020, reflecting a growth rate of around 20% [2]. - The company reported revenue of 216 million yuan and net profit of 95 million yuan for the first three quarters of 2020, marking year-on-year increases of 7.39% and 19.74%, respectively [1][2]. Business Model and Product Offering - Zhenghai Biological specializes in the research, development, production, and sales of biological regenerative materials, including oral and skin repair membranes, and bone repair materials [2]. - The company maintains a high gross margin exceeding 90% since 2012, attributed to its advanced technology [2][3]. Market Challenges - The company faced unprecedented challenges during the COVID-19 pandemic, particularly in its core business areas such as oral and neurosurgery, which were significantly impacted [2].

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Zhenghai Biological, which has a current PE ratio of 33.40, significantly lower than the industry average of 55.41 [1][2] - Zhenghai Biological's market capitalization stands at 4.037 billion yuan, with a total of 16,966 shareholders as of March 31, 2025, indicating a slight decrease in shareholder numbers [1] - The company specializes in the research, production, and sales of bio-regenerative materials, with key products including oral repair membranes and absorbable dura mater patches [1] Group 2 - The latest financial report for the first quarter of 2025 shows that Zhenghai Biological achieved a revenue of 97.42 million yuan, representing an 8.68% year-on-year increase, while net profit decreased by 34.06% to 26.63 million yuan [1] - The gross profit margin for the company is reported at 80.96%, indicating strong profitability despite the decline in net profit [1] - Zhenghai Biological has been recognized as one of the top 50 new material leading enterprises in Shandong Province for 2023, reflecting its industry standing and innovation capabilities [1]

Core Insights - Zhenghai Biological's stock closed at 21.19 yuan, up 1.29%, with a rolling PE ratio of 31.55, marking a 64-day low, and a total market capitalization of 3.814 billion yuan [1] - The average PE ratio in the medical device industry is 51.87, with a median of 37.48, placing Zhenghai Biological at 67th in the industry ranking [1] - The company experienced a net outflow of 1.9014 million yuan in principal funds on July 16, with a total outflow of 12.4302 million yuan over the past five days [1] Company Overview - Zhenghai Biological focuses on the research, production, and sales of biological regenerative materials, with key products including oral repair membranes, absorbable dura mater patches, bone repair materials, and surgical sponges [1] - The company was recognized as one of the top 50 new material leading enterprises in Shandong Province for 2023 [1] Financial Performance - In the first quarter of 2025, Zhenghai Biological reported revenue of 97.4158 million yuan, a year-on-year increase of 8.68%, while net profit was 26.6267 million yuan, reflecting a year-on-year decrease of 34.06%, with a gross profit margin of 80.96% [1]

Company Overview - Zhenghai Biological's closing price on July 8 was 20.85 yuan, up 1.21%, with a rolling PE ratio of 31.05, marking a new low in 58 days, and a total market capitalization of 3.753 billion yuan [1] - The company ranks 67th in the medical device industry, which has an average PE ratio of 51.58 and a median of 37.46 [1] Shareholder Information - As of March 31, 2025, Zhenghai Biological had 16,966 shareholders, a decrease of 193 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Business Focus - Zhenghai Biological specializes in the research, production, and sales of bio-regenerative materials, with key products including oral repair membranes, absorbable dura mater patches, bone repair materials, skin repair membranes, surgical packing sponges, self-etching adhesives, active biological bone, dura mater patches, phosphoric acid etchants, and dental pit and fissure sealants [1] Industry Recognition - The company was included in the 2023 list of leading new material enterprises in Shandong Province, recognized as one of the top 50 new material enterprises [1] Financial Performance - In the first quarter of 2025, Zhenghai Biological reported revenue of 97.42 million yuan, a year-on-year increase of 8.68%, and a net profit of 26.63 million yuan, a year-on-year decrease of 34.06%, with a gross profit margin of 80.96% [1]

Industry Overview - The hard brain (spinal) membrane patch is a sheet-like material used for temporary or permanent repair of defects in the dura mater and/or spinal dura mater [1] - The demand for hard brain (spinal) membrane patches is increasing due to the aging population, rising incidence of cerebrovascular diseases, and improved disease awareness among the public [1][8] - The market size for hard brain (spinal) membrane patches in China is projected to reach 1.18 billion yuan in 2024 and 1.841 billion yuan by 2029 [1][8] Market Status - The artificial hard brain (spinal) membrane patch is primarily used to fill local losses or defects in the dura mater, which is crucial for protecting brain tissue [6] - Since 2020, hard brain (spinal) membrane patches have been included in bulk procurement across 24 provinces in China, leading to significant price reductions, with average price drops of 70%-90% in several provinces [6][8] - The market size for hard brain (spinal) membrane patches had previously expanded significantly from 2016 to 2020 but faced a contraction due to centralized procurement policies [8] Key Enterprises - Major companies in the hard brain (spinal) membrane patch industry include Guanhao Biological, Zhenghai Biological, Maipu Medical, and Bairen Medical, among others [2][12] - Guanhao Biological reported a total revenue of 377 million yuan in 2024, with a year-on-year decline of 6.6% [13] - Zhenghai Biological's revenue for 2024 was 363 million yuan, down 12.19% year-on-year, with its membrane series products generating 149 million yuan [15] Development Trends - Technological innovations such as 3D printing, nanofiber materials, and bioactive composite materials are being increasingly applied in the development and production of hard brain (spinal) membrane patches [17] - The domestic production rate of artificial hard brain (spinal) membrane patches has reached 90%, with companies like Maipu Medical and Guanhao Biological enhancing their technological capabilities [18] - Government policies supporting the medical device industry and stricter regulations are creating a favorable environment for the development of the hard brain (spinal) membrane patch industry [19]